These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 23838274

  • 1. 5-HT1A agonist alleviates serotonergic potentiation of extrapyramidal disorders via postsynaptic mechanisms.
    Shimizu S, Mizuguchi Y, Tatara A, Kizu T, Andatsu S, Sobue A, Fujiwara M, Morimoto T, Ohno Y.
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct 01; 46():86-91. PubMed ID: 23838274
    [Abstract] [Full Text] [Related]

  • 2. Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders.
    Shimizu S, Tatara A, Imaki J, Ohno Y.
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug 16; 34(6):877-81. PubMed ID: 20398719
    [Abstract] [Full Text] [Related]

  • 3. Serotonergic modulation of extrapyramidal motor disorders in mice and rats: role of striatal 5-HT3 and 5-HT6 receptors.
    Ohno Y, Imaki J, Mae Y, Takahashi T, Tatara A.
    Neuropharmacology; 2011 Aug 16; 60(2-3):201-8. PubMed ID: 20813116
    [Abstract] [Full Text] [Related]

  • 4. Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens.
    Ohno Y, Shimizu S, Imaki J, Ishihara S, Sofue N, Sasa M, Kawai Y.
    Neuropharmacology; 2008 Oct 16; 55(5):717-23. PubMed ID: 18585397
    [Abstract] [Full Text] [Related]

  • 5. Serotonin(1A) receptor agonism in the expression of behavioral dopaminergic supersensitivity in subchronic haloperidol treated rats.
    Batool F, Haleem DJ.
    Pak J Pharm Sci; 2008 Oct 16; 21(4):411-20. PubMed ID: 18930864
    [Abstract] [Full Text] [Related]

  • 6. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
    Espejo-Porras F, Fernández-Ruiz J, Pertwee RG, Mechoulam R, García C.
    Neuropharmacology; 2013 Dec 16; 75():155-63. PubMed ID: 23924692
    [Abstract] [Full Text] [Related]

  • 7. Enhancement of serotonin-1A receptor dependent responses following withdrawal of haloperidol in rats.
    Haleem DJ, Khan NH.
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun 16; 27(4):645-51. PubMed ID: 12787852
    [Abstract] [Full Text] [Related]

  • 8. Analysis of the 5-HT1A receptor involvement in passive avoidance in the rat.
    Misane I, Johansson C, Ogren SO.
    Br J Pharmacol; 1998 Oct 16; 125(3):499-509. PubMed ID: 9806333
    [Abstract] [Full Text] [Related]

  • 9. Chronic treatment with fluoxetine decreases cerebral metabolic responses to the 5-HT1A agonist 8-hydroxy-2(di-N-propylamino)tetralin and increases those to the 5-HT2A/2C agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and to the dopaminergic agonist apomorphine.
    Freo U, Merico A, Ermani M, Ori C.
    Brain Res; 2010 Jun 04; 1335():24-34. PubMed ID: 20381465
    [Abstract] [Full Text] [Related]

  • 10. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Tada M, Shirakawa K, Matsuoka N, Mutoh S.
    Psychopharmacology (Berl); 2004 Oct 04; 176(1):94-100. PubMed ID: 15083255
    [Abstract] [Full Text] [Related]

  • 11. Diabetes attenuates the antidepressant-like effect mediated by the activation of 5-HT1A receptor in the mouse tail suspension test.
    Miyata S, Hirano S, Kamei J.
    Neuropsychopharmacology; 2004 Mar 04; 29(3):461-9. PubMed ID: 14628002
    [Abstract] [Full Text] [Related]

  • 12. Receptor-genes cross-talk: effect of chronic 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino) tetralin treatment on the expression of key genes in brain serotonin system and on behavior.
    Popova NK, Naumenko VS, Cybko AS, Bazovkina DV.
    Neuroscience; 2010 Aug 11; 169(1):229-35. PubMed ID: 20423722
    [Abstract] [Full Text] [Related]

  • 13. Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers.
    Christoffersen CL, Meltzer LT.
    Neuropsychopharmacology; 1998 May 11; 18(5):399-402. PubMed ID: 9536454
    [Abstract] [Full Text] [Related]

  • 14. Toward brain imaging of serotonin 5-HT1A autoreceptor internalization.
    Zimmer L, Riad M, Rbah L, Belkacem-Kahlouli A, Le Bars D, Renaud B, Descarries L.
    Neuroimage; 2004 Jul 11; 22(3):1421-6. PubMed ID: 15219613
    [Abstract] [Full Text] [Related]

  • 15. Role of spinal serotonergic pathways in sneeze-induced urethral continence reflex in rats.
    Miyazato M, Kaiho Y, Kamo I, Kitta T, Chancellor MB, Sugaya K, Arai Y, de Groat WC, Yoshimura N.
    Am J Physiol Renal Physiol; 2009 Oct 11; 297(4):F1024-31. PubMed ID: 19640898
    [Abstract] [Full Text] [Related]

  • 16. Quinpirole, 8-OH-DPAT and ketanserin modulate catalepsy induced by high doses of atypical antipsychotics.
    Ninan I, Kulkarni SK.
    Methods Find Exp Clin Pharmacol; 1999 Nov 11; 21(9):603-8. PubMed ID: 10669905
    [Abstract] [Full Text] [Related]

  • 17. Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors.
    Gogos A, Kwek P, Chavez C, van den Buuse M.
    J Pharmacol Exp Ther; 2010 Apr 11; 333(1):218-27. PubMed ID: 20042529
    [Abstract] [Full Text] [Related]

  • 18. Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat?
    Jolas T, Schreiber R, Laporte AM, Chastanet M, De Vry J, Glaser T, Adrien J, Hamon M.
    J Pharmacol Exp Ther; 1995 Feb 11; 272(2):920-9. PubMed ID: 7853210
    [Abstract] [Full Text] [Related]

  • 19. A drug discrimination analysis of the actions of novel serotonin1A receptor ligands in the rat using the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin.
    Schreiber R, Brocco M, Lefèbvre de Ladonchamps B, Monneyron S, Millan MJ.
    J Pharmacol Exp Ther; 1995 Nov 11; 275(2):822-31. PubMed ID: 7473172
    [Abstract] [Full Text] [Related]

  • 20. Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders.
    Tatara A, Shimizu S, Shin N, Sato M, Sugiuchi T, Imaki J, Ohno Y.
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug 07; 38(2):252-9. PubMed ID: 22542492
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.